For­mer Spark ex­ec to lead a gene ther­a­py up­start of his own; Big Phar­ma mar­ket­ing vet named CEO of Swiss biotech

Dave Green­wald’s days as act­ing CEO of Aper­tu­ra Gene Ther­a­py are over as Joseph La Barge steps in to lead the biotech, which just launched in April.

Peer Re­view had been won­der­ing about La Barge’s next land­ing spot since he left Spark at the end of 2021. In his eight-year stretch with the gene ther­a­py pi­o­neer, he be­gan as chief le­gal of­fi­cer and was lat­er pro­mot­ed to CBO in 2019, when Spark was sold to Roche for $4.3 bil­lion. Deer­field, where Green­wald is VP of busi­ness de­vel­op­ment, put up all the fi­nanc­ing for Aper­tu­ra’s $67 mil­lion Se­ries A.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.